- Published on
Medicine – Trichomoniasis: Aetiology, Transmission, Pathogenesis, Clinical Features, Diagnosis and Treatment
1. Introduction to Trichomoniasis
Trichomoniasis is a common sexually transmitted infection (STI) caused by Trichomonas vaginalis, a motile, flagellated protozoan parasite.
The infection primarily affects the lower genitourinary tract and is an important cause of vaginitis and abnormal vaginal discharge.
In women, trichomoniasis may produce a characteristic frothy, yellow-green, foul-smelling vaginal discharge, accompanied by vulval irritation, itching and inflammation.
In men, infection is frequently asymptomatic, although urethritis and other genitourinary symptoms may occasionally occur.
An important feature of trichomoniasis is that many infected individuals have no symptoms but can still transmit the parasite to sexual partners.
The infection is treatable with nitroimidazole antibiotics, particularly metronidazole, and management of sexual partners is essential to reduce reinfection.
2. Aetiological Agent – Trichomonas vaginalis
The causative organism is Trichomonas vaginalis, a unicellular protozoan parasite.
Unlike bacterial sexually transmitted infections such as gonorrhoea and chlamydia, trichomoniasis is caused by a eukaryotic microorganism.
Trichomonas vaginalis is a pear-shaped, flagellated protozoan that uses its flagella and undulating membrane for movement.
The organism exists predominantly in the trophozoite form and does not have a recognised cyst stage.
Its motility is an important characteristic that can be observed during microscopic examination of a fresh clinical specimen.
The parasite primarily inhabits the vagina, urethra and other parts of the lower genitourinary tract.
3. Morphological Characteristics
Trichomonas vaginalis is typically pear-shaped or oval.
It possesses four anterior flagella and an additional recurrent flagellum associated with an undulating membrane.
These structures allow the organism to move rapidly through genital secretions.
It also contains an axostyle, a supporting structure that extends through the body of the parasite.
Under wet-mount microscopy, the organism may demonstrate characteristic jerky or twitching movements.
This motility is a useful diagnostic feature, although microscopy is less sensitive than modern molecular tests.
4. Transmission of Trichomoniasis
Trichomoniasis is transmitted predominantly through sexual contact.
Transmission usually occurs when infected genital secretions come into contact with susceptible mucosal surfaces during sexual activity.
The parasite can spread between sexual partners even when the infected individual has no symptoms.
Transmission is most commonly associated with genital sexual contact.
Unlike some other sexually transmitted infections, Trichomonas vaginalis primarily infects the lower genitourinary tract rather than the bloodstream or distant organs.
Because asymptomatic infection is common, untreated sexual partners can act as reservoirs for continued transmission.
5. Incubation Period
The incubation period of symptomatic trichomoniasis is generally approximately 5–28 days following exposure.
However, many infected individuals remain asymptomatic.
Some patients may develop symptoms only after a prolonged period of infection.
Therefore, the onset of symptoms does not reliably establish the exact timing of acquisition.
Persistent infection can continue for months or longer without appropriate treatment.
Pathogenesis of Trichomoniasis
6. Colonisation of the Genitourinary Tract
Following transmission, Trichomonas vaginalis colonises the epithelial surfaces of the lower genitourinary tract.
In women, the parasite commonly infects the vagina and may also involve the urethra and cervix.
In men, infection most commonly involves the urethra.
The organism adheres to epithelial cells and interacts with the local mucosal environment.
This attachment allows the parasite to persist and contribute to epithelial injury.
7. Development of Vaginal Inflammation
Trichomonas vaginalis causes inflammation through direct interactions with epithelial cells and the host immune response.
The parasite can damage epithelial surfaces and stimulate the release of inflammatory mediators.
This produces redness, swelling and irritation of the vaginal mucosa.
Inflammation also increases vaginal secretions, contributing to abnormal discharge.
The severity of inflammation varies considerably between individuals.
Some patients develop pronounced vaginitis, while others remain asymptomatic despite infection.
8. Changes in Vaginal pH
The normal vaginal environment is generally acidic, with a pH commonly between approximately 3.8 and 4.5 during reproductive years.
This acidic environment is maintained largely by lactobacilli.
Trichomoniasis is commonly associated with an increase in vaginal pH.
Affected patients often have a vaginal pH greater than 4.5.
However, elevated vaginal pH is not specific to trichomoniasis and may also occur in bacterial vaginosis.
Therefore, pH measurement is a supportive finding rather than a definitive diagnostic test.
Clinical Features of Trichomoniasis in Women
9. Vaginal Discharge
The classical presentation of trichomoniasis is abnormal vaginal discharge.
The discharge is traditionally described as yellow-green, frothy and foul-smelling.
It may be relatively thin or abundant.
The unpleasant odour is associated with changes in the vaginal environment and inflammatory secretions.
However, not all patients develop the classical discharge.
Some women have white, grey or yellow discharge, while others have minimal or no noticeable abnormalities.
Therefore, the absence of green or frothy discharge does not exclude trichomoniasis.
10. Vaginitis
Vaginitis refers to inflammation of the vaginal mucosa.
In trichomoniasis, the vaginal epithelium may become erythematous and irritated.
Patients may experience burning, discomfort and increased sensitivity.
Inflammation can produce pain during sexual intercourse and irritation during urination.
Vaginitis may be accompanied by vulval inflammation, producing vulvovaginitis.
The severity ranges from mild irritation to marked inflammation with significant discomfort.
11. Vulval Pruritus
Vulval itching is a common symptom of symptomatic trichomoniasis.
It results from local inflammation and irritation of the vulval tissues.
Patients may experience persistent itching, burning or soreness.
Scratching may produce secondary excoriations and further irritation.
However, vulval pruritus is not specific to trichomoniasis and may also occur in vulvovaginal candidiasis, dermatitis and other genital conditions.
12. Dysuria
Dysuria refers to pain or burning during urination.
Trichomoniasis may produce dysuria because the parasite can infect or irritate the urethral epithelium.
Inflammation of the external genital tissues may also cause discomfort when urine contacts irritated mucosal surfaces.
Patients may therefore present with urinary symptoms despite the absence of a conventional bacterial urinary tract infection.
13. Dyspareunia
Dyspareunia refers to pain during sexual intercourse.
In trichomoniasis, dyspareunia may result from inflammation of the vaginal and vulval mucosa.
The discomfort may be superficial and associated with local irritation.
Some patients may also experience postcoital spotting because inflamed cervical or vaginal tissue can bleed more easily.
Persistent dyspareunia requires assessment for other gynaecological and infectious causes.
14. Strawberry Cervix
A classical examination finding in trichomoniasis is the strawberry cervix, also called colpitis macularis.
This appearance results from punctate haemorrhages and inflammatory changes involving the cervical mucosa.
The cervix may show multiple small red spots against an inflamed background.
These petechial lesions produce an appearance resembling the surface of a strawberry.
Although strawberry cervix is a characteristic association, it is not present in most cases on routine examination.
It may be more readily detected using colposcopy.
Therefore, the absence of a strawberry cervix does not exclude trichomoniasis.
15. Asymptomatic Infection in Women
A substantial proportion of women with trichomoniasis have no noticeable symptoms.
These individuals may still carry the parasite within the lower genital tract.
Asymptomatic infection can persist for prolonged periods.
Despite the absence of symptoms, transmission to sexual partners remains possible.
This is one reason trichomoniasis can continue circulating within sexually active populations.
Clinical Features of Trichomoniasis in Men
16. Asymptomatic Infection
Trichomoniasis is frequently asymptomatic in men.
The organism may colonise the urethra without producing significant inflammation.
Asymptomatic individuals may unknowingly transmit the infection to sexual partners.
Therefore, the absence of urethral symptoms does not exclude infection.
17. Urethritis
When symptomatic, trichomoniasis in men may cause urethritis.
Urethritis is inflammation of the urethral mucosa.
Patients may develop burning during urination, urethral irritation or a small amount of urethral discharge.
The discharge is usually less prominent than the vaginal discharge seen in symptomatic women.
Because these symptoms overlap with gonorrhoea and chlamydia, laboratory testing is important.
18. Other Genitourinary Manifestations
Trichomoniasis may occasionally be associated with irritation of the glans penis or other lower genitourinary symptoms.
Prostatic involvement has also been described, although its clinical significance varies.
Most infected men do not develop severe disease.
Nevertheless, untreated infection can contribute to ongoing transmission and reinfection of sexual partners.
Diagnosis of Trichomoniasis
19. Clinical Suspicion
Trichomoniasis should be considered in patients presenting with abnormal vaginal discharge, vaginal irritation, vulval itching or dysuria.
The combination of frothy yellow-green discharge, elevated vaginal pH and cervical inflammation is suggestive.
However, these findings are not sufficiently specific to establish the diagnosis.
Other conditions, particularly bacterial vaginosis and vulvovaginal candidiasis, can produce overlapping symptoms.
Laboratory testing is therefore important.
20. Wet-Mount Microscopy
Wet-mount microscopy is a traditional diagnostic method for trichomoniasis.
A sample of vaginal secretions is mixed with saline and examined under a microscope.
The presence of motile, flagellated Trichomonas vaginalis trophozoites supports the diagnosis.
The organisms may demonstrate characteristic jerky or twitching movement.
However, wet-mount microscopy has relatively low sensitivity compared with molecular tests.
Its sensitivity also decreases if the specimen is not examined promptly because trophozoite motility diminishes over time.
A negative wet mount therefore does not exclude trichomoniasis.
21. Nucleic Acid Amplification Testing
Nucleic acid amplification tests (NAATs) are the preferred diagnostic tests for trichomoniasis when available.
These tests detect genetic material from Trichomonas vaginalis.
They are considerably more sensitive than conventional wet-mount microscopy.
Depending on the assay, specimens may include vaginal swabs, endocervical samples or urine.
Appropriate specimen selection depends on the patient’s anatomy and the validated test.
NAATs are particularly useful when symptoms are suggestive but microscopy is negative.
22. Vaginal pH Testing
Trichomoniasis is commonly associated with a vaginal pH above 4.5.
This finding reflects disruption of the normal acidic vaginal environment.
However, elevated pH also occurs in bacterial vaginosis.
In contrast, uncomplicated vulvovaginal candidiasis usually occurs with a normal vaginal pH.
Vaginal pH is therefore useful in the differential diagnosis of vaginal discharge but cannot independently confirm trichomoniasis.
23. Culture
Culture methods can be used to detect Trichomonas vaginalis.
They involve placing clinical specimens into specialised media that support parasite growth.
Culture was historically an important diagnostic technique.
However, modern NAATs generally provide superior sensitivity and are more widely preferred when available.
Culture may still have a role in selected circumstances, including specialised investigations.
Treatment of Trichomoniasis
24. Metronidazole
Metronidazole is a first-line treatment for trichomoniasis.
It belongs to the nitroimidazole class of antimicrobial drugs.
Metronidazole enters susceptible microorganisms and undergoes intracellular reduction.
This produces reactive compounds that damage microbial DNA and interfere with nucleic acid synthesis.
The resulting DNA injury inhibits parasite survival and replication.
Metronidazole is active against Trichomonas vaginalis and several anaerobic microorganisms.
25. Recommended Treatment in Women
For women, a commonly recommended regimen is metronidazole 500 mg orally twice daily for seven days.
This multidose regimen is preferred over a single 2 g dose in current CDC guidance for women because it provides better treatment outcomes.
The medication should be taken as prescribed, even if symptoms improve before the course is completed.
Treatment is important because untreated infection may persist and contribute to further transmission.
The precise regimen should follow applicable local clinical guidelines.
26. Recommended Treatment in Men
For men, a commonly recommended regimen is metronidazole 2 g orally as a single dose.
This is the standard regimen in CDC guidance for uncomplicated trichomoniasis in men.
Alternative regimens may be considered according to clinical circumstances and local guidance.
Treatment is important even when symptoms are absent, particularly when a sexual partner has confirmed infection.
27. Tinidazole
Tinidazole is another nitroimidazole antimicrobial agent active against Trichomonas vaginalis.
It has a similar mechanism of action to metronidazole.
A commonly used alternative regimen is tinidazole 2 g orally as a single dose.
Tinidazole may be considered when clinically appropriate, including selected cases of persistent infection.
However, treatment selection depends on pregnancy status, tolerability, availability and relevant guidelines.
28. Treatment of Sexual Partners
Treatment of sexual partners is an essential component of trichomoniasis management.
Sexual partners may carry Trichomonas vaginalis without symptoms.
If only one partner is treated, reinfection can occur after sexual contact resumes.
Therefore, current sexual partners should receive appropriate treatment according to clinical guidance.
Patients should avoid sexual intercourse until they and their partners have completed treatment and symptoms have resolved.
This helps reduce reinfection and ongoing transmission.
29. Persistent or Recurrent Trichomoniasis
Trichomoniasis may persist or recur after treatment.
A common cause is reinfection from an untreated sexual partner.
Other causes include incomplete adherence to medication and, less commonly, antimicrobial resistance.
Patients with persistent symptoms should be reassessed for reinfection, treatment adherence and alternative diagnoses.
When repeat molecular testing is used after treatment, timing matters because residual nucleic acid may remain detectable temporarily.
In women, routine retesting approximately three months after treatment is recommended in CDC guidance because reinfection is common.
30. Adverse Effects of Metronidazole
Metronidazole is generally well tolerated.
Common adverse effects include nausea, abdominal discomfort, headache and a metallic taste.
Occasionally, patients may experience dizziness or gastrointestinal upset.
Rare adverse effects include peripheral neuropathy, particularly with prolonged or repeated exposure.
Metronidazole may interact with certain medications, including warfarin.
Patients should follow the prescribed regimen and seek medical advice if significant adverse effects occur.
Trichomoniasis During Pregnancy
31. Clinical Importance
Trichomoniasis during pregnancy is associated with adverse pregnancy outcomes.
These may include premature rupture of membranes, preterm delivery and low birth weight.
However, an association does not mean that every infected pregnant patient will experience complications.
Symptomatic pregnant patients should be evaluated and treated appropriately.
Metronidazole is generally considered safe for use during pregnancy when indicated.
32. Treatment During Pregnancy
Metronidazole is the recommended treatment for symptomatic trichomoniasis during pregnancy.
The seven-day oral regimen is commonly used.
Available evidence indicates that metronidazole poses a low risk to the developing fetus.
Tinidazole is generally avoided during pregnancy because human safety data are limited.
Treatment decisions should consider the patient’s symptoms, pregnancy stage and applicable obstetric guidance.
Complications of Trichomoniasis
33. Persistent Vaginal Inflammation
Untreated trichomoniasis can produce persistent inflammation of the vaginal mucosa.
Patients may experience recurrent discharge, irritation and discomfort.
Chronic inflammation may interfere with sexual activity and quality of life.
Persistent symptoms also increase the likelihood of repeated healthcare visits and antimicrobial treatment.
34. Increased Susceptibility to HIV
Trichomoniasis is associated with an increased risk of HIV acquisition.
Inflammation of the genital mucosa may disrupt epithelial barriers and recruit immune cells that are susceptible to HIV infection.
This can facilitate viral transmission during sexual exposure.
Trichomoniasis may also increase genital HIV shedding in individuals living with HIV.
Appropriate diagnosis and treatment are therefore important components of sexual health care.
35. Adverse Pregnancy Outcomes
Maternal trichomoniasis has been associated with preterm delivery, premature rupture of membranes and low birth weight.
The mechanisms may involve local genital inflammation and alterations in the reproductive tract environment.
Treatment of symptomatic infection is recommended, although treatment does not guarantee prevention of every associated pregnancy complication.
Differential Diagnosis of Vaginal Discharge
36. Trichomoniasis
Trichomoniasis is caused by the flagellated protozoan Trichomonas vaginalis.
The classical discharge is frothy, yellow-green and foul-smelling.
Vaginal pH is commonly above 4.5.
Patients may experience itching, dysuria and dyspareunia.
A strawberry cervix may occasionally be present.
Treatment involves oral metronidazole or an appropriate alternative.
37. Bacterial Vaginosis
Bacterial vaginosis is associated with disruption of normal vaginal microbiota and a reduction in protective lactobacilli.
It commonly produces a thin, homogeneous, grey-white discharge with a fishy odour.
Vaginal pH is typically above 4.5.
Microscopy may reveal clue cells, which are vaginal epithelial cells coated with bacteria.
Bacterial vaginosis is not caused by Trichomonas vaginalis.
Metronidazole is also used in its treatment, but routine partner treatment is not generally recommended in the same way as for trichomoniasis.
38. Vulvovaginal Candidiasis
Vulvovaginal candidiasis is most commonly caused by Candida albicans.
It typically produces thick, white, curd-like vaginal discharge.
Marked vulval itching and irritation are common.
The discharge is usually not strongly malodorous.
Vaginal pH generally remains within the normal acidic range.
Treatment involves antifungal medication, such as topical clotrimazole or oral fluconazole in appropriate non-pregnant patients.
39. Important Examination Distinction
The three classical causes of abnormal vaginal discharge have different characteristic features.
Trichomoniasis → Frothy, yellow-green, foul-smelling discharge with possible strawberry cervix.
Bacterial vaginosis → Thin, grey-white discharge with fishy odour and clue cells.
Vulvovaginal candidiasis → Thick, white, curd-like discharge with prominent itching.
These patterns are useful for examinations, but clinical appearances overlap and laboratory testing may be necessary.
Prevention of Trichomoniasis
40. Safer Sexual Practices
Trichomoniasis can be prevented by reducing exposure to infected genital secretions.
Consistent and correct condom use reduces transmission risk.
However, condoms do not eliminate the risk of all sexually transmitted infections.
Patients with confirmed infection should avoid sexual activity until treatment has been completed by themselves and their partners.
41. Screening for Other Sexually Transmitted Infections
Patients diagnosed with trichomoniasis should be assessed for other sexually transmitted infections when appropriate.
Testing may include HIV, syphilis, gonorrhoea and chlamydia.
This is important because different sexually transmitted infections may coexist.
Identifying and treating associated infections helps prevent complications and further transmission.
Important Corrections and Clarifications
42. Causative Organism
The original notes correctly identify Trichomonas vaginalis as the cause of trichomoniasis.
It is a flagellated protozoan parasite rather than a bacterium or fungus.
The organism exists as a motile trophozoite and does not have a recognised cyst stage.
43. Characteristic Vaginal Discharge
The original notes correctly describe foul-smelling, greenish-yellow vaginal discharge as a characteristic feature.
The discharge may also be frothy.
However, this appearance is not present in every patient.
Many infected individuals have mild symptoms or remain asymptomatic.
44. Vaginitis
Trichomoniasis is an important cause of infectious vaginitis.
It produces inflammation of the vaginal mucosa, leading to irritation, itching, burning and sometimes dyspareunia.
A strawberry cervix is a classical but relatively uncommon finding.
45. Treatment with Metronidazole
The original notes correctly identify metronidazole as a treatment for trichomoniasis.
For women, the preferred CDC regimen is oral metronidazole 500 mg twice daily for seven days.
For men, oral metronidazole 2 g as a single dose is commonly recommended.
Sexual partners should also be treated to prevent reinfection.
Important Clinical Associations – Note Form
46. Trichomonas vaginalis
Trichomonas vaginalis is a motile, flagellated protozoan parasite.
It causes a sexually transmitted infection primarily affecting the lower genitourinary tract.
It exists in the trophozoite form without a recognised cyst stage.
47. Vaginal Discharge
The classical discharge is frothy, yellow-green and foul-smelling.
However, the appearance is variable, and some patients have minimal discharge.
48. Strawberry Cervix
Strawberry cervix refers to punctate cervical haemorrhages associated with inflammation.
It is a classical examination finding in trichomoniasis but is not present in most cases.
49. Vaginal pH
Trichomoniasis commonly increases vaginal pH above 4.5.
An elevated pH supports the diagnosis but is not specific.
Bacterial vaginosis may produce a similar pH change.
50. Wet-Mount Microscopy
Wet-mount microscopy may demonstrate motile, flagellated trophozoites.
The organisms show characteristic jerky movements.
However, microscopy has limited sensitivity compared with NAATs.
51. NAAT Testing
Nucleic acid amplification testing is the preferred diagnostic approach when available.
It detects Trichomonas vaginalis genetic material with high sensitivity.
52. Metronidazole
Metronidazole is a nitroimidazole antimicrobial drug.
It damages microbial DNA following intracellular activation.
It is a first-line treatment for trichomoniasis.
53. Partner Treatment
Sexual partners should receive appropriate treatment because asymptomatic infection is common.
Treating partners reduces reinfection and continued transmission.
Key Clinical Pattern
The defining feature of trichomoniasis is infectious vaginitis caused by the flagellated protozoan Trichomonas vaginalis, classically producing frothy, yellow-green, foul-smelling vaginal discharge.
Trichomonas vaginalis → Flagellated protozoan parasite.
Transmission → Predominantly sexual contact.
Typical vaginal discharge → Frothy, yellow-green and foul-smelling.
Vaginitis → Vaginal inflammation, itching, irritation and burning.
Strawberry cervix → Punctate cervical haemorrhages.
Vaginal pH → Usually greater than 4.5.
Wet-mount microscopy → Motile, flagellated trophozoites.
NAAT → Preferred diagnostic test when available.
Metronidazole → First-line treatment.
Women → Metronidazole 500 mg orally twice daily for seven days.
Men → Metronidazole 2 g orally as a single dose.
Sexual partners → Require treatment to reduce reinfection.
Asymptomatic infection → Common, particularly in men.
HIV association → Genital inflammation may increase susceptibility to HIV acquisition.
For examinations, remember the classical association: Trichomonas vaginalis causes frothy, foul-smelling, yellow-green vaginal discharge, may produce a strawberry cervix, and is treated with oral metronidazole.
